Wei-fan Hsu
Taitung, TNQ, Taiwan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 60 publications
Systemic Treatment Strategies for Recurrent Hepatocellular Carcinoma Following Liver Transplantation: A 20-y Retrospective Analysis With Clinical Insights.
Journal: Transplantation
Published: May 01, 2026
Absence of steatosis combined with cardiometabolic risk factors confers the highest hepatocellular carcinoma risk in treated chronic hepatitis B.
Journal: Annals of medicine
Published: April 20, 2026
Immune Checkpoint Inhibitors for Recurrent Hepatocellular Carcinoma After Liver Transplantation: Safety Under an Immunosuppression-Preserving Strategy.
Journal: Annals of transplantation
Published: March 24, 2026
Atezolizumab plus Bevacizumab versus Lenvatinib as First-Line Treatment for Unresectable Hepatocellular Carcinoma Stratified by the CRAFITY Score: An International Multicenter Study.
Journal: Liver cancer
Published: February 06, 2026
Determinants of long-term survival from atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.
Journal: European journal of cancer (Oxford, England : 1990)
Published: November 28, 2025
Addition of Intra-Arterial Therapy to Immunotherapy Improves Outcomes in Unresectable Hepatocellular Carcinoma: Taiwan Multicenter Cohort Study.
Journal: Liver cancer
Published: November 13, 2025
Metabolic and liver stiffness measures for hepatocellular carcinoma risk stratification after viral eradication in chronic hepatitis C.
Journal: Journal of the Formosan Medical Association = Taiwan yi zhi
Published: September 21, 2025
A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab plus bevacizumab in hepatocellular carcinoma.
Journal: Journal of hepatology
Published: September 04, 2025
Clinical implications of fibrosis marker dynamics after hepatitis C cure: Insights from paired biopsies.
Journal: Journal of the Formosan Medical Association = Taiwan yi zhi
Published: August 28, 2025
Prediction Model for Risk of Hepatocellular Carcinoma After Hepatitis C Viral Eradication.
Journal: Journal of hepatocellular carcinoma
Published: July 09, 2025
Editorial: Beyond Viral Eradication-Scrutinising Outcomes After Hepatitis C Cure.
Journal: Alimentary pharmacology & therapeutics
Published: June 05, 2025
Last Updated: 09/26/2026